ALSO NOTED: CSL Behring wins OK for new indication; Helix BioPharma touts new data; and much more...

> The FDA has announced its approval for an additional indication for CSL Behring's Rhophylac, an anti-D Rh immunoglobulin. Release

> Canada's Helix BioPharma announced positive results from its phase II clinical study of its Topical Interferon Alpha-2b in women with human papilloma virus induced low-grade cervical lesions. Release

> Heralding a major milestone in the four-year-old collaboration between India's Ranbaxy and GlaxoSmithKline, researchers say they have identified a respiratory drug candidate for pre-clinical development. In the pact, Ranbaxy will be responsible for Phase I and II studies while GSK will take over all subsequent research. Report

> Looking to enhance its reputation in microbiology, BioMerieux is buying Spain's BioMedics for $5.5 million. Report

> Abbott Laboratories has asked U.S. and European regulators to approve Humira for moderate to severe chronic plaque psoriasis. Report

> GSK has submitted Tykerb for approval in Japan against breast cancer. Report

> Japan's Daiichi Sankyo is transferring commercial rights to the anti-clotting drug Panaldine to France's Sanofi-Aventis. Report

And Finally… Drug companies spent $155 million on federal lobbying in the 18 months through June of last year, according to a report from the Center for Public Integrity. Much of that money was spent passing a provision that bars regulators from negotiating drug prices for the Medicare pharmacy benefit. Report